- Home
- DVAX vs UDMY Comparison
DVAX vs UDMY Comparison
Compare DVAX & UDMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- UDMY
- Stock Information
- Founded
- DVAX 1996
- UDMY 2009
- Country
- DVAX United States
- UDMY United States
- Employees
- DVAX N/A
- UDMY N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- UDMY Other Consumer Services
- Sector
- DVAX Health Care
- UDMY Real Estate
- Exchange
- DVAX Nasdaq
- UDMY Nasdaq
- Market Cap
- DVAX 1.3B
- UDMY 1.1B
- IPO Year
- DVAX 2004
- UDMY 2021
- Fundamental
- Price
- DVAX $11.36
- UDMY $7.45
- Analyst Decision
- DVAX Buy
- UDMY Buy
- Analyst Count
- DVAX 4
- UDMY 11
- Target Price
- DVAX $26.25
- UDMY $10.10
- AVG Volume (30 Days)
- DVAX 1.6M
- UDMY 1.3M
- Earning Date
- DVAX 08-05-2025
- UDMY 07-30-2025
- Dividend Yield
- DVAX N/A
- UDMY N/A
- EPS Growth
- DVAX N/A
- UDMY N/A
- EPS
- DVAX N/A
- UDMY N/A
- Revenue
- DVAX $294,620,000.00
- UDMY $790,019,000.00
- Revenue This Year
- DVAX $21.18
- UDMY $1.87
- Revenue Next Year
- DVAX $16.83
- UDMY $4.15
- P/E Ratio
- DVAX N/A
- UDMY N/A
- Revenue Growth
- DVAX 24.76
- UDMY 5.43
- 52 Week Low
- DVAX $9.22
- UDMY $5.68
- 52 Week High
- DVAX $14.63
- UDMY $10.61
- Technical
- Relative Strength Index (RSI)
- DVAX 66.09
- UDMY 60.13
- Support Level
- DVAX $10.38
- UDMY $6.80
- Resistance Level
- DVAX $11.48
- UDMY $7.34
- Average True Range (ATR)
- DVAX 0.30
- UDMY 0.24
- MACD
- DVAX 0.08
- UDMY 0.05
- Stochastic Oscillator
- DVAX 90.40
- UDMY 78.69
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.